Stock Events

Stock Events

Tempest Therapeutics 

$1.0400
133
+$0.02+1.96% Friday 20:00
+$0.06+5.77%Friday 23:58After hours

Statistics

Day High
1.04
Day Low
1.04
52W High
12.23
52W Low
0.84
Volume
3,432
Avg. Volume
-
Mkt Cap
16.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-4.03
-2.78
-1.53
-0.28
Expected EPS
-0.35
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-26.26MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TPST. It's not an investment recommendation.
Tesla
16
TSLA
Amazon
15
AMZN
NVIDIA
15
NVDA
AMD
13
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb is a leading biopharmaceutical company focusing on cancer therapies, directly competing with Tempest Therapeutics' oncology focus.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is a global healthcare company that develops cancer drugs, competing in the same therapeutic areas as Tempest Therapeutics.
Pfizer
PFE
Mkt Cap152.69B
Pfizer Inc. has a broad portfolio of oncology drugs, making it a direct competitor in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, Inc. is known for its strong presence in the oncology sector, competing with Tempest Therapeutics in developing cancer therapies.
AMGEN
AMGN
Mkt Cap224.63B
Amgen Inc. focuses on human therapeutics, including oncology, which puts it in direct competition with Tempest Therapeutics.
Novartis
NVS
Mkt Cap286.78B
Novartis AG is a multinational pharmaceutical company with a significant focus on oncology, competing in the same market as Tempest Therapeutics.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a major player in the oncology market, with a wide range of cancer treatments that compete with Tempest Therapeutics.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca PLC has a strong oncology portfolio, making it a key competitor in the cancer therapy market.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, develops cancer drugs, competing with Tempest Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals, Inc. is involved in developing treatments for cancer, among other diseases, competing in the oncology space with Tempest Therapeutics.

About

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Show more...
CEO
Matthew Angel
Employees
4
Country
United States
ISIN
US87978U2078
WKN
000A41556

Listings

MU
DE
3OS0.MU
F
DE
3OS0.F
STU
DE
3OS0.STU
MU
DE
3OS.MU

0 Comments

Share your thoughts

FAQ

What is Tempest Therapeutics stock price today?▼
The current price of TPST is $1.04 USD — it has increased by +1.96% in the past 24 hours. Watch Tempest Therapeutics stock price performance more closely on the chart.
What is Tempest Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Tempest Therapeutics stocks are traded under the ticker TPST.
Is Tempest Therapeutics stock price growing?▼
TPST stock has fallen by -7.96% compared to the previous week, the month change is a +12.32% rise, over the last year Tempest Therapeutics has showed a -79.25% decrease.
What is Tempest Therapeutics market cap?▼
Today Tempest Therapeutics has the market capitalization of 16.62M
When is the next Tempest Therapeutics earnings date?▼
Tempest Therapeutics is going to release the next earnings report on November 11, 2026.
What were Tempest Therapeutics earnings last quarter?▼
TPST earnings for the last quarter are -0.34 USD per share, whereas the estimation was -0.3 USD resulting in a -13.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tempest Therapeutics revenue for the last year?▼
Tempest Therapeutics revenue for the last year amounts to 0 USD.
What is Tempest Therapeutics net income for the last year?▼
TPST net income for the last year is -26.26M USD.
How many employees does Tempest Therapeutics have?▼
As of August 24, 2026, the company has 4 employees.
In which sector is Tempest Therapeutics located?▼
Tempest Therapeutics operates in the Health & Wellness sector.
When did Tempest Therapeutics complete a stock split?▼
The last stock split for Tempest Therapeutics was on January 30, 2026 with a ratio of 2:1.
Where is Tempest Therapeutics headquartered?▼
Tempest Therapeutics is headquartered in BRISBANE, United States.